Bone disease and skeletal complications in patients with β thalassemia major.

[1]  E. Terpos,et al.  Treatment options for thalassemia patients with osteoporosis , 2010, Annals of the New York Academy of Sciences.

[2]  E. Neufeld,et al.  Pain as an emergent issue in thalassemia , 2010, American journal of hematology.

[3]  M. Cappellini,et al.  Deferasirox (Exjade®) for the Treatment of Iron Overload , 2009, Acta Haematologica.

[4]  S. Colella,et al.  Osteoprotegerin and RANKL in the pathogenesis of osteoporosis in patients with thalassaemia major. , 2009, Panminerva medica.

[5]  Khaled M Musallam,et al.  Iron Overload: Consequences, Assessment, and Monitoring , 2009, Hemoglobin.

[6]  M. Cappellini,et al.  Overview of Iron Chelation Therapy with Desferrioxamine and Deferiprone , 2009, Hemoglobin.

[7]  E. Kastritis,et al.  Serum Dickkopf-1 is increased and correlates with reduced bone mineral density in patients with thalassemia-induced osteoporosis. Reduction post-zoledronic acid administration , 2008, Haematologica.

[8]  I. Holm,et al.  Bone Disease in Thalassemia: A Frequent and Still Unresolved Problem , 2008, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[9]  H. Kulkarni,et al.  Bone recovery after zoledronate therapy in thalassemia-induced osteoporosis: a meta-analysis and systematic review , 2009, Osteoporosis International.

[10]  E. Terpos,et al.  Continuous improvement of bone mineral density two years post zoledronic acid discontinuation in patients with thalassemia-induced osteoporosis: long-term follow-up of a randomized, placebo-controlled trial , 2008, Haematologica.

[11]  M. Cappellini,et al.  Bone demineralization in adult thalassaemic patients: contribution of GH and IGF‐I at different skeletal sites , 2008, Clinical endocrinology.

[12]  G. Luleci,et al.  Relationship between SP1 polymorphism and osteoporosis in β‐thalassemia major patients , 2008, Pediatrics international : official journal of the Japan Pediatric Society.

[13]  R. Mahfouz,et al.  Vitamin D receptor genotypes and response to zoledronic acid therapy in thalassemia-induced osteoporosis , 2008, Annals of Hematology.

[14]  E. Vichinsky,et al.  Fracture prevalence and relationship to endocrinopathy in iron overloaded patients with sickle cell disease and thalassemia. , 2006, Bone.

[15]  G. Ossenkoppele,et al.  High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome (vol 93, pg 1894, 2008) , 2007 .

[16]  M. Cappellini,et al.  Growth hormone deficiency (GHD) in adult thalassaemic patients , 2007, Clinical endocrinology.

[17]  G. Russo,et al.  The “lively” cytokines network in β-Thalassemia Major-related osteoporosis , 2007 .

[18]  G. Tolis,et al.  MARKERS OF BONE METABOLISM IN EUGONADAL FEMALE PATIENTS WITH β-THALASSEMIA MAJOR , 2007 .

[19]  M. Bekheirnia,et al.  BONE MINERAL DENSITY IN IRANIAN ADOLESCENTS AND YOUNG ADULTS WITH β-THALASSEMIA MAJOR , 2007 .

[20]  B. Larijani,et al.  Serum zinc and its relation to bone mineral density in β-thalassemic adolescents , 2004, Biological Trace Element Research.

[21]  A. F. Ghiam,et al.  Bone mineral density in beta-thalassemia major and intermedia. , 2007, Indian pediatrics.

[22]  G. Tolis,et al.  Circulating osteoprotegerin and receptor activator of NF-κB ligand system in patients with β-thalassemia major , 2006, Journal of Bone and Mineral Metabolism.

[23]  E. Vichinsky,et al.  Increased prevalence of iron‐overload associated endocrinopathy in thalassaemia versus sickle‐cell disease , 2006, British journal of haematology.

[24]  M. Athanassiou-Metaxa,et al.  Effect of zoledronic acid on markers of bone turnover and mineral density in osteoporotic patients with beta-thalassaemia , 2006, Annals of Hematology.

[25]  D. Bowden,et al.  A Randomized, Double-Blind, Placebo-Controlled Trial of Intravenous Zoledronic Acid in the Treatment of Thalassemia-Associated Osteopenia , 2006, Calcified Tissue International.

[26]  R. Mahfouz,et al.  Intravenous zoledronic acid treatment in thalassemia-induced osteoporosis: results of a phase II clinical trial , 2006, Annals of Hematology.

[27]  G. Di Fede,et al.  Low serum levels of 25-hydroxy vitamin D in adults affected by thalassemia major or intermedia. , 2006, Bone.

[28]  E. Neufeld,et al.  Prevalence of fractures among the Thalassemia syndromes in North America. , 2006, Bone.

[29]  G. Tolis,et al.  Evaluation of Bone Mineral Density of the Lumbar Spine in Patients With β-Thalassemia Major With Dual-Energy X-Ray Absorptiometry and Quantitative Computed Tomography: A Comparison Study , 2006, Journal of pediatric hematology/oncology.

[30]  V. De Sanctis,et al.  Chelation Therapy and Bone Metabolism Markers in Thalassemia Major , 2006, Journal of pediatric endocrinology & metabolism : JPEM.

[31]  E. Terpos,et al.  Zoledronic acid for the treatment of osteoporosis in patients with beta-thalassemia: results from a single-center, randomized, placebo-controlled trial. , 2006, Haematologica.

[32]  A. Chuansumrit,et al.  Association between bone mineral density and erythropoiesis in Thai children and adolescents with thalassemia syndromes , 2006, Journal of Bone and Mineral Metabolism.

[33]  M. Hall-Craggs,et al.  Degenerative disc disease as a cause of back pain in the thalassaemic population: a case-control study using MRI and plain radiographs , 2006, Skeletal Radiology.

[34]  M. Vogiatzi,et al.  Low Bone Mineral Density in Adolescents with β‐Thalassemia , 2005, Annals of the New York Academy of Sciences.

[35]  V. Lee,et al.  Bone mineral density in children with thalassaemia major: determining factors and effects of bone marrow transplantation , 2005, Bone Marrow Transplantation.

[36]  M. Mylona,et al.  Comparison of DXA, QCT and trabecular structure in β‐thalassaemia , 2005 .

[37]  E. Terpos,et al.  Osteoprotegerin to soluble receptor activator of nuclear factor κ‐B ligand ratio is reduced in patients with thalassaemia‐related osteoporosis who receive vitamin D3 , 2005, European journal of haematology.

[38]  E. Eren,et al.  Biochemical markers of bone turnover and bone mineral density in patients with β‐thalassaemia major , 2005, International journal of clinical practice.

[39]  C. Vullo,et al.  Growth and development in thalassaemia major patients with severe bone lesions due to desferrioxamine , 1996, European Journal of Pediatrics.

[40]  P. Babyn,et al.  Spinal deformities in deferoxamine-treated homozygous beta-thalassemia major patients , 2005, Pediatric Radiology.

[41]  E. Terpos,et al.  New insights into the pathophysiology and management of osteoporosis in patients with beta thalassaemia , 2004, British journal of haematology.

[42]  T. Tanaka,et al.  Oxidative Stress-induced DNA Damage in the Synovial Cells of the Temporomandibular Joint in the Rat , 2004, Journal of dental research.

[43]  N. Frisina,et al.  Osteoprotegerin and RANKL in the Pathogenesis of Thalassemia‐Induced Osteoporosis: New Pieces of the Puzzle , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[44]  V. Perifanis,et al.  Treatment of beta‐thalassaemia‐associated osteoporosis with zoledronic acid , 2004, British journal of haematology.

[45]  A. Saxena,et al.  Deferiprone, efficacy and safety , 2004, Indian journal of pediatrics.

[46]  G M Bydder,et al.  Ultrashort echo time (UTE) MRI of the spine in thalassaemia. , 2004, The British journal of radiology.

[47]  J. Margulies,et al.  Bone density, mineral content, and cortical index in patients with thalassemia major and the correlation to their bone fractures, blood transfusions, and treatment with desferrioxamine , 1992, Calcified Tissue International.

[48]  A. Cnaan,et al.  Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. , 2004, Haematologica.

[49]  E. Terpos,et al.  Pamidronate is an effective treatment for osteoporosis in patients with beta‐thalassaemia , 2003, British journal of haematology.

[50]  R. Rajatanavin,et al.  Abnormalities in Bone Mineral Density and Bone Histology in Thalassemia , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[51]  R. Galanello,et al.  Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. , 2003, Blood.

[52]  M. Bekheirnia,et al.  Metabolic and endocrinologic complications in beta-thalassemia major: a multicenter study in Tehran , 2003, BMC endocrine disorders.

[53]  A. Chuansumrit,et al.  Bone histomorphometry in children and adolescents with beta-thalassemia disease: iron-associated focal osteomalacia. , 2003, The Journal of clinical endocrinology and metabolism.

[54]  A. Chuansumrit,et al.  Bone mineral density, biochemical and hormonal profiles in suboptimally treated children and adolescents with β‐thalassaemia disease , 2003 .

[55]  A. Piga,et al.  Bone mass and metabolism in thalassemic children and adolescents treated with different iron-chelating drugs , 2003, Journal of Bone and Mineral Metabolism.

[56]  P. Pennisi,et al.  Quantitative ultrasound of bone and clodronate effects in thalassemia-induced osteoporosis , 2003, Journal of Bone and Mineral Metabolism.

[57]  G. Vitale,et al.  Hypogonadism and Hormone Replacement Therapy on Bone Mass of Adult Women with Thalassemia Major , 2003, Calcified Tissue International.

[58]  Sheila M. Williams,et al.  How Many Children Remain Fracture-Free During Growth? A Longitudinal Study of Children and Adolescents Participating in the Dunedin Multidisciplinary Health and Development Study , 2002, Osteoporosis International.

[59]  N. Frisina,et al.  Bisphosphonates in the Treatment of Thalassemia-Induced Osteoporosis , 2002, Osteoporosis International.

[60]  P. Korovessis,et al.  Natural History of Untreated Scoliosis in &bgr;-Thalassemia , 2002, Spine.

[61]  A. Coppola,et al.  Effect of VDR polymorphisms on growth and bone mineral density in homozygous beta thalassaemia , 2002, British journal of haematology.

[62]  Chi-kong Li,et al.  Patterns of bone diseases in transfusion-dependent homozygous thalassaemia major: predominance of osteoporosis and desferrioxamine-induced bone dysplasia , 2002, Pediatric Radiology.

[63]  N. Frisina,et al.  Osteoporosis and β-thalassemia major: Role of the IGF-I/IGFBP-III axis , 2002 .

[64]  T. Ulutin,et al.  Polymorphism analysis in the COLIA1 gene of patients with thalassemia major and intermedia. , 2002, Haematologia.

[65]  B. Wonke.  Clinical management of -Thalassemia major , 2001 .

[66]  E. Terpos,et al.  Bone resorption is increased in young adults with thalassaemia major , 2001, British journal of haematology.

[67]  M. Buemi,et al.  Effects of Hormonal Replacement Therapy on Bone Metabolism in Young Adults with Beta-thalassemia Major , 2001, Osteoporosis International.

[68]  M. Idelson,et al.  Bone mineral metabolism in adults with β‐thalassaemia major and intermedia , 2000 .

[69]  S. Perrotta,et al.  Osteoporosis in β‐thalassaemia major patients: analysis of the genetic background , 2000, British journal of haematology.

[70]  Yongwon Choi,et al.  Diverse roles of the tumor necrosis factor family member TRANCE in skeletal physiology revealed by TRANCE deficiency and partial rescue by a lymphocyte-expressed TRANCE transgene. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[71]  Y. Chan,et al.  Desferrioxamine-induced long bone changes in thalassaemic patients - radiographic features, prevalence and relations with growth. , 2000, Clinical radiology.

[72]  P. Korovessis,et al.  Correlative analysis of the sagittal profile of the spine in patients with beta-thalassemia and in healthy persons. , 2000, Journal of spinal disorders.

[73]  Vullo,et al.  Safety profile of the oral iron chelator deferiprone: a multicentre study , 2000, British journal of haematology.

[74]  S. Morony,et al.  OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis , 1999, Nature.

[75]  F. Gumruk,et al.  Beta Thalassaemia: A Report of 20 Children , 1999, Clinical Rheumatology.

[76]  Prescott,et al.  High prevalence of low bone mass in thalassaemia major , 1998, British journal of haematology.

[77]  A. Piga,et al.  Bone Metabolism in Thalassemia a , 1998, Annals of the New York Academy of Sciences.

[78]  E. Vichinsky.  The Morbidity of Bone Disease in Thalassemia , 1998, Annals of the New York Academy of Sciences.

[79]  S. Morony,et al.  osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. , 1998, Genes & development.

[80]  B. Ansari,et al.  Bone mineral density in prepubertal children with beta-thalassemia: correlation with growth and hormonal data. , 1998, Metabolism: clinical and experimental.

[81]  D. Pezzoli,et al.  Growth hormone secretion and bone histomorphometric study in thalassaemic patients with acquired skeletal dysplasia secondary to desferrioxamine. , 1998, Journal of pediatric endocrinology & metabolism : JPEM.

[82]  A. Piga,et al.  Bone density and metabolism in thalassaemia. , 1998, Journal of pediatric endocrinology & metabolism : JPEM.

[83]  A. Hoffbrand,et al.  Genetic and acquired predisposing factors and treatment of osteoporosis in thalassaemia major. , 1998, Journal of pediatric endocrinology & metabolism : JPEM.

[84]  E. Di Battista,et al.  Long-term follow-up of skeletal dysplasia in thalassaemia major. , 1998, Journal of pediatric endocrinology & metabolism : JPEM.

[85]  B. Wonke.  Bone disease in beta-thalassaemia major. , 1998, British journal of haematology.

[86]  A. Hoffbrand,et al.  Incidence of endocrine complications and clinical disease severity related to genotype analysis and iron overload in patients with β‐thalassaemia , 1997, European journal of haematology.

[87]  P. Korovessis,et al.  Incidence of Scoliosis in β-Thalassemia and Follow-Up Evaluation , 1996 .

[88]  P. Korovessis,et al.  Prevalence of scoliosis in beta-thalassemia. , 1996, Journal of spinal disorders.

[89]  W. Berdon,et al.  Deferoxamine-induced platyspondyly in hypertransfused thalassemic patients , 1995, Pediatric Radiology.

[90]  G. Gedikoğlu,et al.  Growth and Puberty in Thalassemia Major , 1995, Journal of pediatric endocrinology & metabolism : JPEM.

[91]  E. Rachmilewitz,et al.  Hydroxyl radical generation in β-thalassemic red blood cells , 1995 .

[92]  Margarita L. G. Anapllotou,et al.  The contribution of hypogonadism to the development of osteoporosis in thalassaemia major: new therapeutic approaches , 1995, Clinical endocrinology.

[93]  N. Akar,et al.  Effects of calcitonin therapy on osteoporosis in patients with thalassemia. , 1995, Acta haematologica.

[94]  R. Lindsay,et al.  Prevention and treatment of osteoporosis , 1993, The Lancet.

[95]  M. Freedman,et al.  Growth failure and bony changes induced by deferoxamine. , 1992, The American journal of pediatric hematology/oncology.

[96]  P. Korovessis,et al.  Scoliosis in β Thalassemia , 1991, Pediatrics.

[97]  P. Giardina,et al.  Deferoxamine-induced bone dysplasia in patients with thalassemia major. , 1991, AJR. American journal of roentgenology.

[98]  Johanson Na.  Musculoskeletal problems in hemoglobinopathy. , 1990 .

[99]  S. Posen,et al.  Osteoporosis in hemochromatosis: iron excess, gonadal deficiency, or other factors? , 1989, Annals of internal medicine.

[100]  F. Cucca,et al.  Deferoxamine-induced growth retardation in patients with thalassemia major. , 1988, The Journal of pediatrics.

[101]  Alan R. Cohen,et al.  Incidence and treatment of fractures in thalassemia. , 1988, Journal of orthopaedic trauma.

[102]  A. Finsterbush,et al.  Fracture patterns in thalassemia. , 1985, Clinical orthopaedics and related research.

[103]  R. Girot,et al.  Calcium phosphate metabolism and bone disease in patients with homozygous thalassemia. , 1982, The Journal of clinical endocrinology and metabolism.

[104]  J. Burnell,et al.  Relation between erythropoiesis and bone metabolism in thalassemia. , 1981, The New England journal of medicine.

[105]  J. Insall,et al.  Supracondylar osteotomy in thalassemia. , 1978, Clinical orthopaedics and related research.

[106]  D. Dines,et al.  Fractures in thalassemia. , 1976, The Journal of bone and joint surgery. American volume.

[107]  J. B. Clegg,et al.  The thalassaemia syndromes , 1965 .

[108]  T. B. Cooley,et al.  ANEMIA IN CHILDREN: WITH SPLENOMEGALY AND PECULIAR CHANGES IN THE BONES REPORT OF CASES , 1927 .